Clinical trials
Vasculitis clinical trials
Below are recruiting vasculitis clinical trials, each written for real people, not researchers. We’re tracking 99 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07160608RecruitingPhase 2
Study of Tarperprumig for ANCA-associated vasculitis
This trial tests a new drug (tarperprumig) for people with active ANCA-associated vasculitis (GPA or MPA). The goal is to see if it is safe and effective for treating the disease, especially when standard treatments like rituximab or cyclophosphamide are being considered.
Ciudad de Buenos AiresAges 18–80 - NCT07258524Recruiting
Vasculitis PET scan trial for heart disease risk
This trial uses a special PET scan to look at inflammation in blood vessels and check heart disease risk in people with active ANCA-associated vasculitis (AAV). It may help doctors understand how to better manage heart health during treatment.
EdinburghAges 18 years+ - NCT05946564RecruitingPhase 3
Pioglitazone to protect kidney function in ANCA vasculitis
This Phase 3 trial tests whether pioglitazone can help protect kidney function in people with newly diagnosed or relapsing ANCA-associated vasculitis that is actively affecting the kidneys. It aims to improve “renal tolerance,” meaning your kidneys may be better able to tolerate the disease and treatment.
AmiensAges 18–80 - NCT07388277RecruitingPhase 1/Phase 2
CAR T-cell therapy for ANCA vasculitis
This trial tests a new CAR T-cell therapy (CC-97540) for people with active ANCA vasculitis (GPA or MPA) that has not responded to or has returned after standard treatments. The goal is to see if this personalized cell therapy can calm the immune system and reduce disease activity.
Boston, MassachusettsAges 18 years+ - NCT07010250Recruiting
Kidney Energy Use and Scarring in ANCA Vasculitis
This study looks at how kidney cells use energy and how that leads to scarring in people with ANCA vasculitis. It compares findings with people who have other kidney diseases to better understand and possibly treat kidney damage.
ParisAges 18–90 - NCT07586137Recruiting
Understanding Systemic Vasculitis: A Long-Term Health Study
This study follows people with systemic vasculitis (inflammation of blood vessels throughout the body) to better understand how the disease progresses and what outcomes to expect. Researchers will collect health information over time to improve treatment and care for vasculitis patients.
Pavia, PaviaAges 18 years+ - NCT07664228Recruiting
Predicting stomach pain in children with IgA vasculitis
This study looks at a blood test done when a child is first diagnosed with IgA vasculitis (also called Henoch-Schönlein purpura) to see if it can predict stomach or intestine problems. It involves one extra blood draw at diagnosis and a follow-up visit a few weeks later.
Bursa, BursaAges 2–18 - NCT03755245Enrolling by invitation
Imaging study using a tracer to measure inflammation in joints and lungs
This trial tests how a radioactive imaging medicine (a tracer called 68Ga-DOTA-Siglec-9) spreads in the body and how well it shows inflammation. It includes both healthy volunteers and people with active rheumatoid arthritis, vasculitis, or pulmonary sarcoidosis to see if the scan matches disease activity.
TurkuAges 18–70 - NCT06733935RecruitingPhase 1/Phase 2
Study of NKX019 for immune diseases
This trial tests an investigational cell therapy called NKX019 for people with certain autoimmune diseases like scleroderma, myositis, vasculitis, or rheumatoid arthritis. It aims to see if NKX019 can help control the disease when standard treatments have not worked well enough.
Orange, CaliforniaAges 18–75 - NCT07556484RecruitingPhase 1
Avacopan Delivery Through Feeding Tube for Severe Vasculitis
This trial tests a new way to deliver avacopan—a drug that reduces inflammation in rare blood vessel diseases (ANCA-associated vasculitis)—through a feeding tube instead of by mouth. The study measures how much of the drug reaches your bloodstream and checks if it's safe for patients with very severe disease who are on a breathing machine.
Rochester, MinnesotaAges 18 years+ - NCT07203404RecruitingEarly Phase 1
A study of a universal CAR-T cell therapy for autoimmune diseases
This trial tests a new treatment called RD06-05, which uses specially engineered immune cells to target and potentially reset parts of the immune system that are attacking your own body. It is being studied for several autoimmune conditions like lupus, vasculitis, kidney diseases, and more.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07089121RecruitingPhase 1/Phase 2
Descartes-08 for young people with autoimmune diseases
This trial tests a new therapy called Descartes-08 for children, teens, and young adults with autoimmune conditions like lupus, myasthenia gravis, or dermatomyositis. It aims to see if it can help control moderate disease that hasn't responded well enough to other treatments.
Washington D.C., District of ColumbiaAges 12 years+ - NCT03290456Recruiting
Prednisone plus rituximab to help keep ANCA vasculitis in remission
This trial studies whether extending low-dose prednisone alongside rituximab (given as infusions at set times) helps keep microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) in remission. If you respond to initial treatment, the goal is to reduce the chance of relapse and maintain disease control.
AmiensAges 18 years+ - NCT04871191RecruitingPhase 3
Salvage treatment for granulomatosis with polyangiitis flare
This Phase 3 trial studies “salvage” treatment for people with active granulomatosis with polyangiitis (GPA) whose standard treatments have not worked well enough. It aims to improve disease control and reduce the need for ongoing higher-dose steroids.
ParisAges 18 years+ - NCT04919538Recruiting
Long-term study of relapsing polychondritis
This study follows people who have been diagnosed with relapsing polychondritis over time. It aims to better understand the condition and how it progresses, which may help future care.
Philadelphia, PennsylvaniaAges Any age - NCT05003986RecruitingPhase 2
Sparsentan for children with protein leaking kidney diseases
This Phase 2 study tests sparsentan in children with certain kidney diseases that cause high amounts of protein in the urine. It aims to see if the medicine can reduce kidney damage signals and protein leakage compared with standard care.
Los Angeles, CaliforniaAges 1–17 - NCT05012033Recruiting
Study how high-dose steroids move through the body
This study measures blood levels of high-dose steroid medicines (prednisolone or related steroids) to understand how the body processes them in different real-life situations. It may help improve how steroids are dosed and monitored for people needing short-term or longer-term anti-inflammatory treatment.
LondonAges 18–75 - NCT05017142Recruiting
Pediatric brain inflammation registry for Swiss patients
This study is a registry that collects health information from children and teens in Switzerland diagnosed with certain inflammatory brain and spinal cord conditions. It helps researchers understand these illnesses better over time and may guide future treatments.
Aarau, Canton of AargauAges Up to 36 years - NCT05251415Recruiting
Study of rare autoimmune diseases with blood and medical samples
This trial collects clinical and lab information (like blood and medical history) from people with rare autoimmune diseases, especially when symptoms are unusual. It aims to better understand what causes these illnesses and how newer treatments may help.
ToulouseAges 6–99 - NCT05315141Recruiting
Study of AAV in people with ANCA-associated vasculitis
This study follows people with ANCA-associated vasculitis to better understand the treatment using AAV. Your participation would mainly involve agreeing to be in the study and meeting the study’s disease criteria.
Changsha, HunanAges Any age - NCT05565885Recruiting
Blood test study to find markers in adult vasculitis
This study looks for blood test markers that may help diagnose vasculitis and predict how it may go. You may be offered additional blood sampling if you have certain active vasculitis conditions.
ToursAges 16 years+ - NCT05628948Recruiting
Donate blood for a heart and metabolism research biobank
This study builds a “biobank,” which is a collection of blood and related samples, to support future research on heart and metabolic (sugar/body-fat) conditions. It may help researchers better understand these diseases and improve future prevention and treatments.
Cleveland, OhioAges 18 years+ - NCT05904301Recruiting
Registry for autoimmune and autoinflammatory disease patients
This study builds a nationwide list (registry) of people with certain autoimmune or inflammation-related illnesses. It helps researchers understand these diseases better over time, which can guide future care.
YerevanAges Any age - NCT05935709Recruiting
Danish database study for GCA or PMR
This study builds and uses a Danish database for people diagnosed with giant cell arteritis (GCA) or polymyalgia rheumatica (PMR). It may help doctors learn more about these conditions over time and improve care.
AarhusAges 50 years+
Hear when a new Vasculitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for vasculitis?
- Yes. Clin2 currently lists 99 recruiting vasculitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a vasculitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a vasculitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.